

RESEARCH

Open Access



Efficient bone regeneration of BMP9-stimulated human periodontal ligament stem cells (hPDLSCs) in decellularized bone matrix (DBM) constructs to model maxillofacial intrabony defect repair

Yuxin Zhang^{1,2}, Wenping Luo^{1,3}, Liwen Zheng^{1,2}, Jing Hu^{1,2}, Li Nie^{1,3}, Huan Zeng^{1,2}, Xi Tan^{1,2}, Yucan Jiang^{1,2}, Yeming Li^{1,2}, Tianyu Zhao^{1,3}, Zhuohui Yang^{1,2}, Tong-Chuan He⁴ and Hongmei Zhang^{1,2*} 

Abstract

Background: BMP9-stimulated DPSCs, SCAPs and PDLSCs are effective candidates for repairing maxillofacial bone defects in tissue engineering, while the most suitable seed cell source among these three hDMSCs and the optimal combination of most suitable type of hDMSCs and BMP9 have rarely been explored. Moreover, the orthotopic maxillofacial bone defect model should be valuable but laborious and time-consuming to evaluate various candidates for bone regeneration. Thus, inspired from the maxillofacial bone defects and the traditional *in vivo* ectopic systems, we developed an intrabony defect repair model to recapitulate the healing events of orthotopic maxillofacial bone defect repair and further explore the optimized combinations of most suitable hDMSCs and BMP9 for bone defect repair based on this modified ectopic system.

Methods: Intrabony defect repair model was developed by using decellularized bone matrix (DBM) constructs prepared from the cancellous part of porcine lumbar vertebral body. We implanted DBM constructs subcutaneously on the flank of each male NU/NU athymic nude mouse, followed by directly injecting the cell suspension of different combinations of hDMSCs and BMP9 into the central hollow area of the constructs 7 days later. Then, the quality of the bony mass, including bone volume fraction (BV/TV), radiographic density (in Hounsfield units (HU)) and the height of newly formed bone, was measured by micro-CT. Furthermore, the H&E staining and immunohistochemical staining were performed to exam new bone and new blood vessel formation in DBM constructs.

Results: BMP9-stimulated periodontal ligament stem cells (PDLSCs) exhibited the most effective bone regeneration among the three types of hDMSCs in DBM constructs. Furthermore, an optimal dose of PDLSCs with a specific extent of BMP9 stimulation was confirmed for efficacious new bone and new blood vessel formation in DBM constructs.

*Correspondence: hmzhang@hospital.cqmu.edu.cn

¹ Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, The Affiliated Hospital of Stomatology of Chongqing Medical University, 426 Songshibei Road, Chongqing 401147, China
Full list of author information is available at the end of the article



Conclusions: The reported intrabony defect repair model can be used to identify optimized combinations of suitable seed cells and biological factors for bone defect repair and subsequent development of efficacious bone tissue engineering therapies.

Keywords: Bone defect, Human dental mesenchymal stem cells (hDMSCs), BMP9, Decellularized bone matrix (DBM) construct, Intrabony defect repair model

Background

The integrity of maxillofacial bone is critical to human oral health and has important supporting and protecting functions [1], although reconstruction and repair of severe bone defects caused by trauma or tumors remain major clinical challenges [2]. In these circumstances, the use of autografts and allografts are popular strategies in clinical treatment [3, 4]. However, the limited source, donor site morbidity, immune rejection and laborious procedures hamper bone graft applications [4–6]. Recently, the use of tissue engineering strategies represents a promising alternative approach [7, 8]. With the increased exploration of various seed cells and biological factors, which could be candidates for bone regeneration, the optimal combinations should be effectively determined for regenerative medicine.

Constructing the orthotopic defects in maxillofacial bone to evaluate various combinations of candidate factors for bone defect repair is the gold standard, while these studies could be time consuming and needed elaborate surgical procedures [9]. Ectopic bone formation systems, which is commonly in the way of directly injecting biofactor-stimulated cell suspensions subcutaneously on the flanks of mice, are considered alternative methods for evaluating bone tissue engineering *in vivo* since they are economical and easy to be carried out [10]. However, the use of traditional ectopic systems has limitations since they lack a bony environment, which is vital for bone remodeling process [9, 11]. Furthermore, the shapes of the newly formed bony masses could be irregular. Due to these aspects, the use of traditional ectopic systems may undermine the evaluation efficiency. Decellularized bone matrix (DBM) can supply a microenvironment similar to the *in vivo* bone defect [12]. Therefore, developing a modified ectopic system by DBM should provide an intrabony environment for evaluating bone tissue engineering therapies, which could also limit cell suspension within a controlled space.

The source of stem cells is wide-ranged, and different seed cell sources exhibit distinct outcomes in mesenchymal stem cells (MSCs)-based therapies. Human dental mesenchymal stem cells (hDMSCs) exhibit multiple lineage differentiation potential, including robust new

bone and new dentin formation for tissue engineering [13, 14]. Thus, hDMSCs may be used as critical seed cells to support and promote maxillofacial bone defect repair. Dental pulp stem cells (DPSCs), periodontal ligament stem cells (PDLSCs) and apical papillary stem cells (SCAPs) are among the common dental stem cells reported to possess more clinical application prospects [15–17], as they can be obtained from distinct dental tissue sources and exhibit distinct biological characteristics and differentiation capacities [18]. Therefore, it is important to compare the osteogenic potential of these distinct sources of hDMSCs *in vivo* and to identify the most efficacious one for tissue engineering use.

Numerous biological factors have been demonstrated to augment the osteogenic differentiation activity of hDMSCs, which are also recognized as the rate-limiting step of effective tissue engineering [19]. Bone morphogenetic proteins (BMPs) have been demonstrated to play important roles in bone regeneration [20]. In our comprehensive analysis of 14 types of human BMPs, we demonstrated that BMP9 is one of the most potent factors that can induce osteogenic differentiation of mesenchymal stem cells (MSCs) and play critical roles in tooth and alveolar bone development although BMP9 is one of the least studied BMPs [21–26]. In recent years, the potent osteogenic capability of hDMSCs stimulated with BMP9 has been demonstrated both *in vivo* and *in vitro* [27]. However, the distinct types of hDMSCs may possess distinct osteogenic activity in response to the stimulation of BMP9. Besides, the dosage of stem cells required for efficacious bone regeneration may be reduced with the help of powerful biofactors. Thus, it is conceivable that the combination of hDMSCs and BMP9 can be further optimized for efficacious bone formation in tissue engineering applications.

In this study, we created an intrabony defect repair model by using decellularized bone matrix (DBM) constructs from the cancellous part of a porcine lumbar vertebral body with a defined bone structure to serve as modified ectopic systems, and then explored the optimal combination of suitable hDMSCs and BMP9 for effective bone regeneration in our fabricated constructs to model the repair of orthotopic maxillofacial bone defects.

Methods

Preparation of ring-shaped decellularized and demineralized bone matrix (rsDBM) disks

The rsDBM construct was prepared from adult porcine lumbar vertebral bodies (Fig. 1C). Briefly, normal and fresh lumbar vertebral tissue was obtained from a local slaughter house (Rongchang, Chongqing, China). After the remnant periosteum, muscle, and soft tissue were removed, the vertebral body was cut to 3 mm and 0.5 mm in thickness using a hard tissue microtome (Exakt 300

CP, Germany). After being washed with distilled water, the bone tissue was cut into either 5.7-mm-diameter and 3-mm-thick bone disks or 5.7-mm-diameter and 0.5-mm-thick disks from the middle region of the lumbar vertebral bone. The ring-shaped bone disks were further prepared from 5.7-mm-diameter and 3-mm-thick disks by removing the central 3 mm of bone tissue with a dental bur, resulting in hollow bone disks with a 5.7 mm outer diameter and 3 mm inner diameter. All bone disks were rinsed and soaked in PBS for 4 h at 4 °C, decellularized in




Fig. 1 Design purpose and preparation process of the decellularized bone matrix (DBM) constructs. **A** Schematic representation of the proposed maxillofacial intrabony defect-inspired model using DBM. **B** Schematic depiction of the fabrication process of the DBM constructs. **C** Schematic representation of the modified ectopic system using fabricated DBM constructs

1% Triton X-100 for 12–24 h at 37 °C, degreased in 25 ml methanol at room temperature with gentle agitation and then soaked in 10 to 30 ml 100% ethanol for 4 h. Finally, the bone disks were rinsed with sterile PBS containing Pen-Strep and stored at –80 °C until use.

Fabrication and characterization of DBM constructs

A typical cylinder-shaped DBM construct used in this study was composed of two parts, a 3-mm-thick hollow bone disk and a 0.5-mm-thick “bottom” bone disk, which were glued together with a light curing dental bonding agent and light cured resin. The resulting hollow cylindrical container was measured with an outer diameter of 5.7 mm, inner diameter of 3 mm and overall thickness of 3.5 mm (Fig. 3B). The compression tests of the DBM constructs were conducted with a universal testing machine (C43.104, MTS, USA) with a constant deformation rate of 1 mm/min. The elastic modulus was calculated from the linear region of the stress–strain curve. The compressive strength was determined from the stress–strain curve using the 0.2% offset method. Three samples were tested in each group.

Isolation and characterization of human dental mesenchymal stem cells (hDMSCs)

The use of human dental samples from clinical procedures was approved by the Ethics Committee of The Affiliated Hospital of Stomatology, Chongqing Medical University (CQHS-REC-2022 (LSNo.15)). All subjects enrolled in the study signed the informed consent form. The methods of isolation and culture of dental stem cells were described previously [28–30]. Briefly, after the removal of teeth, periodontal ligament tissue was harvested with a sterile scalpel by scraping the middle one-third of the tooth root. Dental pulp tissue was collected after sectioning the crown using a dental drill, while apical papilla was obtained from the apical part of the dental papilla. All collected tissues were cut into small pieces and then digested with type I collagenase (Sigma, USA) for 30 min, followed by culturing in α -MEM (HyClone, New York, USA) containing 1% penicillin/streptomycin and 10% fetal bovine serum (FBS, HyClone, New York, USA) at 37 °C in 5% CO₂. Culture medium was changed every three days until the primary cells migrated out of the tissue and reached confluence. Cells at passage 3 were used in the experiments. The expression of stem cell surface markers of hDMSCs was characterized by means of flow cytometry. The fluorescence-labeled antibodies were CD90-FITC (Sino Biological, China), CD29-FITC (Sino Biological, China) and CD45-FITC (Sino Biological, China) as previously described [31–33].

Generation and amplification of recombinant adenoviruses expressing BMP9 and GFP

The HEK-293 or 293pTP cell line was used for adenovirus generation and amplification [34]. Recombinant adenoviruses expressing BMP9 (Ad-BMP9) and green fluorescent protein (Ad-GFP) were generated with AdEasy technology as previously reported [22, 23, 25]. Polybrene (10 μ g/ml; Solarbio, Beijing, China) was applied to improve viral infection efficiency [35].

Osteogenic induction

Primary hDMSCs were seeded in 10-cm cell culture dishes and infected with the indicated multiplicity of infection (MOI) of Ad-BMP9 or Ad-GFP. The GFP signal of the infected hDMSCs was detected under a fluorescence microscope (Carl Zeiss Microimaging GmbH, Göttingen, Germany) 24 h after infection. The GFP positivity of the hDMSCs was used as an indicator of the infection efficiency. The hDMSCs were harvested 24 h after infection for subcutaneous injection into DBM construct.

RNA isolation and real-time quantitative PCR (RT-qPCR)

Total RNA was extracted from Ad-BMP9 or Ad-GFP infected SCAPs, DPSCs and PDLSCs using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.). 2 μ g total RNA was transcribed into cDNA with the use of reverse transcription reaction kit (Invitrogen; Thermo Fisher Scientific, Inc.) in a volume of 20 μ L. The obtained cDNA samples were diluted three-fold with nuclease-free water. All RT-qPCR reactions were conducted using 2 \times SYBR-Green qPCR Master Mix (Bimake, Houston, TX, USA). The qPCR cycles were 95 °C for 3 min, followed by 39 cycles at 95 °C for 10 s, 59 °C for 30 s, and one cycle at 95 °C for 5 s, 65–95 °C, incremented by 0.5 °C for 5 s. At the end of qPCR, the melting curve test was performed to validate the specificity of every primer pair. The $x = 2^{-\Delta\Delta Ct}$ formula was used to calculate relative mRNA expression levels. Three technical replicates were utilized for every sample. *GAPDH* was used to be a reference gene. The primer sequences of the used genes are shown in Additional file 1: Table S1.

Animal studies

All animal experiments were in compliance with the Animals (Scientific Procedures) Act (1986), and the approval of all procedures was granted by the Ethics Committee of The Affiliated Hospital of Stomatology, Chongqing Medical University [CQHS-REC-2022 (LSNo.15)]. Animal studies were divided into two parts, and a total of 25 specific pathogen-free (SPF) NU/NU athymic nude mice (6–8 weeks old, male, 20–25 g weight) were purchased from Beijing Vital River Laboratory Animal Technology

Co., Ltd (11 mice for the first part of the experiment, followed by 14 mice after obtaining the result in the first section). The athymic nude mice were allowed three consecutive days for stabilization of physiological responses before the experiment began, and they were kept in ventilated cages at a temperature of 20°C to 24°C and maintained on a 12/12-h light/dark cycle with a maximum density of 5 mice per cage. All the surgeries were carried out in the dedicated laboratory and the mice were anesthetized with isoflurane (3–4% for anesthesia induces and 1–1.5% for anesthesia maintenance; 21–23% O₂, balance N₂), with two DBM constructs subcutaneously implanted on the flank of each mouse. A total of 48 DBM constructs were implanted and randomly divided into the following 16 groups (including 21 DBM constructs with 11 athymic nude mice in the first part of animal experiment and 27 DBM constructs with 14 athymic nude mice in the second part): The PBS/DBM construct (negative control group), GFP-DPSCs/DBM construct, BMP9-DPSCs/DBM construct, GFP-SCAPs/DBM construct, BMP9-SCAPs/DBM construct, GFP-PDLSCs/DBM construct, BMP9-PDLSCs/DBM construct, 1 × 10⁶ PDLSCs-BMP9 0.7/DBM construct, 1 × 10⁶ PDLSCs-BMP9 1.2/DBM construct, 1 × 10⁶ PDLSCs-BMP9 2.3/DBM construct, 2 × 10⁶ PDLSCs-BMP9 0.7/DBM construct, 2 × 10⁶ PDLSCs-BMP9 1.2/DBM construct, 2 × 10⁶ PDLSCs-BMP9 2.3/DBM construct, 3 × 10⁶ PDLSCs-BMP9 0.7/DBM construct, 3 × 10⁶ PDLSCs-BMP9 1.2/DBM construct, and 3 × 10⁶ PDLSCs-BMP9 2.3/DBM construct, were designed for the following experiments. GFP affected hDMSCs were used as the positive groups. Computer-based random-order generator was used to generate random numbers. The single DBM construct implanted on the flank of athymic nude mouse was the experimental unit and three experimental units were involved per group. A small sample size was selected for each group, since the use of our designed DBM construct was assessed in vivo the first time. Therefore, the present study enabled us gain basic evidence for using BMP9-hDMSC-DBM construct in more complex conditions. One week after implantation, the harvested cells suspended in 40 μl PBS were injected into the hollow area of the DBM constructs. All surgeries were done by the same surgeon during the period of 8:30am to 17:30 pm, and the experiment orders were randomized. The mice were monitored once daily for the wound healing condition after surgery, as well as the food and water intake, weight and activity. If the wound occurred severe suppurative infection or the weight of the mice decreased 20% compared to the weight before, the euthanasia should be used in advance. For each animal, investigators responsible for the data analysis were unaware of the group allocations, while the investigators responsible for the allocation and

the surgery were aware of the group allocations, since the colors of pure PBS differed from the Ad-GFP or Ad-BMP9 affected cell suspensions in PBS.

Micro-CT analysis

The animals were included in the study if they underwent successful DBM constructs implantation and injection treatment, defined by the almost healed conditions of wounds. The animals were excluded if severe inflammatory reaction occurred, or if the animal died prematurely, preventing the collection of Micro-CT and histological data. Included animals were killed with CO₂ Euthanasia System (30–70% rate of the CO₂ replacement per minute) 8 weeks post injection. The DBM constructs were harvested and fixed in 4% PBS buffered formalin (Solarbio; Beijing, China) for 2 days. The samples were scanned with micro-CT (Viva CT 40; Scanco Medical, Bassersdorf, Switzerland) at 70 kVp and 114 uA with a 15 μm voxel size. The acquired images were analyzed by using Mimics Research 19.0 software (Materialise, Lefen, Belgium) and 3-matic Research 11.0 software (Materialise, Lefen, Belgium) to evaluate newly formed bone, bone volume fraction (BV/TV), radiographic density (in Hounsfield units (HU)) and the height of newly formed bone. The two-dimensional (2D) images of the samples were reconstructed into three-dimensional (3D) models by importing the micro-CT DICOM dataset into Mimics Research 19.0 software (Materialise, Lefen, Belgium). The newly formed bone inside or outside the DBM constructs was also extracted for further analyses. Grayscale-based material properties were assigned to the volumetric mesh of new bone tissues based on Mimics Research 19.0 software (Materialise, Lefen, Belgium). The relationship between the Hounsfield units (HU) and new bone density related to porcine lumbar vertebrae was determined as previously described [36–38].

Histologic evaluation and immunohistochemical staining

The harvested DBM constructs were fixed in 4% PBS buffered formalin, decalcified with EDTA solution and embedded in paraffin. The samples were serially sectioned. At least three sections from each sample were chosen for hematoxylin and eosin (H&E) staining. We also carried out trichrome staining on the selected sections. The staining results were recorded under a bright-field microscope (YC. YX—2050, Japan).

Immunohistochemical staining was conducted using the retrieved DBM construct sections. Rabbit anti-OCN (Servicebio, GB11233, 1:200), Rabbit anti-CD31 (Servicebio, GB113151, 1:600) antibody and rabbit anti-α-SMA (Servicebio, GB111364, 1:1000) antibody were used as the primary antibodies. The Streptavidin Peroxidase (SP) Kit (ZSGB-BIO, China) and diaminobenzidine (DAB)

Peroxidase Substrate Kit (ZSGB-BIO, China) were used for the detection of staining. The absence of primary antibody groups was used as a negative control. The staining results were recorded under a bright-field microscope (YC. YX—2050, Japan). The acquired images were analyzed by using Image-Pro Plus 6.0 software (Media Cybernetics, USA) to evaluate Integrated Optical Density (IOD) for quantitative analysis.

Statistical analysis

The quantitative data are presented as the mean \pm SD, as all quantitative experiments were conducted in triplicate. Student's *t* tests or one-way ANOVA tests performed with SPSS 21.0 were used to determine the statistical significance. The data normality test was carried out by SPSS 21.0 with the approach of normal probability plots to determine whether the data of the analysis were normally distributed and met the assumptions of the statistical approaches. $P < 0.05$ was considered statistically significant.

Results

The modified ectopic system DBM constructs can be reproducibly fabricated

To design a modified ectopic system, the maxillofacial intrabony defect-inspired model was utilized (Fig. 1A). Cylindrical-shaped DBM constructs with uniformly distributed trabecular pore properties were prepared from adult porcine lumbar vertebral body bone (Fig. 1B). Specifically, instead of directly injecting the cell suspension into the subcutaneous area, we designed a modified ectopic system that involved two procedures: first, subcutaneously implanting the DBM constructs, followed by injecting the cell suspension into the hollow area of the DBM constructs 7 days later (Fig. 1C). To assess the structural features of the trabecular bone disks, we scanned L4–L5 lumbar vertebrae samples with micro-CT (Fig. 2A, B). As shown in the radiographs, the selected area of the lumbar vertebrae for DBM construction exhibited a uniform porous structure (Fig. 2B).

To fabricate the DBM constructs, sectioned bone disks were subjected to decellularization, demineralization and digestion, resulting in a white, sponge-like structure (Fig. 2C). To provide adequate space for new bone regeneration, we designed a novel cylinder-shaped DBM construct, which appeared as a cylinder of 5.7 mm in outer diameter and 3 mm in inner diameter with a 0.5-mm-thick bone disk cemented to a 3-mm-thick hollow bone disk (Fig. 2C). Micro-CT imaging of the construct further confirmed the uniformity of the porous structure and the interconnected pores after decellularization (Fig. 2D).

Next, we measured the biomechanical characteristics of the DBM constructs and carried out compression

tests; thus, stress–strain curves of the DBM construct were obtained (Fig. 2E). The construct showed an equivalent stress of 24.70 ± 1.73 MPa and a Young's modulus of 689.53 ± 73.51 MPa, as demonstrated in Fig. 2F, G. These results indicated that the DBM construct exhibited sufficient compressive strength to support new bone regeneration and possessed a better cushioning capacity under stress.

Primary DPSCs, SCAPs and PDLSCs stimulated by BMP9 are three convenient candidate cell sources for maxillofacial bone defect repair

To evaluate the suitable cell sources for effective maxillofacial bone defect repair through our DBM constructs, which may recapitulate the bone regeneration events, BMP9-stimulated DPSCs, SCAPs and PDLSCs were chosen as candidate sources of osteoprogenitors. The bright-field images showed that primary hDMSCs grew well and appeared fibroblast-like fusiform (Fig. 3A). Flow cytometric analysis confirmed that the dental MSC markers CD90 and CD29 were highly expressed in these DMSCs, while the hematopoietic marker CD45 was negative (Fig. 3B), indicating that the isolated primary cells in this study possessed the characteristics of MSCs.

We next augmented the osteogenic ability of hDMSCs by infecting them with Ad-BMP9. GFP signals were detected in DPSCs, SCAPs and PDLSCs at 24 h after infection with Ad-BMP9 or Ad-GFP at an MOI of 1.4 (the dilution of the virus at which 75% of cells were infected) (Fig. 4A). To determine whether BMP9 induces the osteogenic activity of hDMSCs, the *in vitro* quantitative assays were carried out. We previously identified some significant early responsive target genes of BMP9 in MSCs like ID1, ID2 and CTGF [39–45]. We infected SCAPs, DPSCs and PDLSCs with Ad-GFP or Ad-BMP9 for 24 h, and the expression levels of ID1, ID2 and CTGF were significantly up-regulated when stimulated by BMP9 (Additional file 1: Fig. S1A). Furthermore, BMP9 was also demonstrated to induce the expression levels of osteogenic transcription factors RUNX2, osteopontin (OPN), alkaline phosphatase (ALP) and osterix (OSX) in hDMSCs at day 3 and/or day7 (Additional file 1: Fig. S1B). Following with this, the designed ectopic intrabony defect repair model was utilized to assess the osteogenic activity of these three BMP9-stimulated hDMSCs *in vivo* (Fig. 4B–D). Specifically, the plain DBM constructs (without cells) were subcutaneously implanted into athymic nude mice, with the hollow bone disk facing upward (Fig. 4B). After 7 days, the primary hDMSCs infected with Ad-BMP9 or Ad-GFP were subcutaneously injected into the hollow area of the implanted DBM construct (Fig. 4C).




Fig. 2 Characterization of the decellularized bone matrix (DBM) constructs. **A** Representative μ CT images of porcine lumbar vertebrae bone at the vertical section. **B** A μ CT image of a horizontal section of porcine lumbar vertebrae bone. The dotted circles in the image denote the selected area for DBM constructs. **C** Representative photographs of the processed DBM constructs. The 5.7-mm-outer diameter and 3-mm-inner diameter ring-shaped bone disk was stuck to the 5.7-mm-diameter bone disk to form a hollow construct. **D** Representative reconstructed 3D μ CT images of the DBM constructs showing their porous structure. **E** DBM constructs were subjected to compression experiments in vitro, including stress–strain curve, equivalent stress (**F**) and modulus elasticity (**G**) of the DBM constructs in the compression test

BMP9-stimulated PDLSCs induced the strongest bone formation efficiency among the three types of hDMSCs in the DBM constructs

To assess the evaluation efficiency of our modified ectopic system and screen for the most suitable type of hDMSCs stimulated by BMP9 for bone defect repair, we compared the osteogenic effect of these three distinct hDMSCs stimulated by BMP9 in our DBM constructs. The micro-CT imaging analysis revealed that significant new bone formation occurred inside the defect area of the DBM constructs. The net new bone tissues were extrapolated by subtracting original DBM constructs from the whole constructs based on the different thresholds of the constructs and the regenerated mineralized matrix (Fig. 5A). 3D reconstruction analysis of the newly formed bone revealed that the BMP9-PDLSCs/DBM construct group had a significantly larger volume of new bone than the other groups (Fig. 5B), suggesting that under the same conditions, BMP9-restored PDLSCs in the DBM constructs may yield the most robust new bone formation inside the defect. Further bone density distribution analysis of the micro-CT imaging reconstructions revealed that new bone densities varied significantly among the groups, while the BMP9-PDLSCs/DBM construct group exhibited the highest bone density among the three BMP9 treatment groups (Fig. 5C). We also analyzed the net new bone formation, new bone volume fraction (BV/TV) and radiographic density (in Hounsfield units (HU)) in the tested construct groups and found that while the BMP9-DPSCs/DBM and BMP9-SCAP/DBM construct groups filled their total volumes (i.e., BV/TV) by $24.47 \pm 0.97\%$ and $27.16 \pm 0.85\%$, the BMP9-PDLSCs/DBM construct group's BV/TV increased to $33.48 \pm 1.29\%$ (Fig. 5D, E). Consistent with the BV/TV results, the average HU in the BMP9-PDLSCs/DBM construct group was the highest among the three BMP9 treatment groups (Fig. 5D, E).

Further analysis of the sagittal plane of micro-CT imaging results for the retrieved bony masses revealed that the BMP9-DPSCs/DBM, BMP9-SCAP/DBM and BMP9-PDLSCs/DBM construct groups all possessed a newly formed bony mass that exceeded the inner space of the DBM constructs, indicating robust osteogenic activities of the hDMSCs in the presence of BMP9 (Additional file 1: Fig. S2A), which was further confirmed by the quantitative analysis of the new bone height based on micro-CT imaging data (Additional file 1: Fig. S3).

Nonetheless, it is noteworthy that various degrees of new bone formation were observed in the PBS/DBM construct group, although the new bone deposition was limited to the inner edges of the construct, confirming the osteoinductive activity of the DBM constructs. Moreover, the DBM construct containing GFP-transduced hDMSCs showed increased osteogenic activity compared with the DBM construct without cells (Additional file 1: Fig. S4). Collectively, these results indicated that while the DBM construct itself was insufficient to initiate a robust bone healing program, the presence of DMSCs (especially PDLSCs) and BMP9 effectively promoted new bone formation in the modified ectopic system *in vivo*. Based on the results gained in this part, we selected PDLSCs as the most suitable seed cells among these three types of hDMSCs for the following experiments.

An optimal dose of PDLSCs with a specific extent of BMP9 stimulation is adequate to promote efficacious new bone formation in DBM constructs

To investigate whether the DBM construct can be used as a measuring tool to estimate approximate dose of stem cells for specific-sized bone defect repair, as well as explore the optimal combination of PDLSCs and BMP9, we infected PDLSCs at six different MOIs (0.2, 0.4, 0.5, 0.7, 1.2 and 2.3) without observing apparent cytotoxicity and chose MOIs of 0.7, 1.2 and 2.3 for the following experiments (Fig. 6A). The total cell numbers of PDLSCs varied from 1×10^6 /construct to 3×10^6 /construct, in which the cells were infected with Ad-BMP9 at MOIs of 0.7, 1.2 and 2.3 (Fig. 6A). After 8 weeks, mineralized projections inside the constructs were observed by micro-CT imaging, and representative 3D reconstructed images of the retrieved samples, including both regenerated mineralized matrix and intrabony defect constructs, showed new bone formation (Fig. 6B). As shown in 3D reconstructed images, the volumes of new bone were significantly augmented in a correlation with increased Ad-BMP9 MOIs, which did not exhibit obvious differences among groups with distinct cell concentrations but the same MOI (Fig. 6B). Quantitative analysis of micro-CT imaging data with the new bone volume fraction (BV/TV) and radiographic density (in Hounsfield units (HU)) further confirmed the results (Fig. 6C, D).

The retrieved bony masses from three different cell doses at the same Ad-BMP9 MOI of 2.3 nearly repaired the whole defect area inside the DBM

(See figure on next page.)

Fig. 3 Isolation and characterization of primary human dental mesenchymal stem cells (hDMSCs). **A** Morphology of primary human DPSCs, SCAPs and PDLSCs. Primary human DPSCs, SCAPs and PDLSCs were isolated from different dental tissue sections and photographed at the indicated times (3, 5 and 7 days). Representative images are shown. **B** The expression of the mesenchymal stem cell surface markers CD90 and CD29 and the hematopoietic marker CD45 in isolated primary human DPSCs, SCAPs and PDLSCs was detected by flow cytometry





Fig. 3 (See legend on previous page.)



constructs (Fig. 6B), and compared to BMP9 MOIs of 0.7 and 1.2 (Additional file 1: Fig. S2B), the new bone tissue exceeded the inner space of the DBM constructs (Fig. 6E). Quantitative analysis of the micro-CT images further revealed that there was no obvious difference in the new bone height among these three groups with distinct cell concentrations but the same MOI (2.3) (Fig. 6F). These results suggested that compared to cell doses of 2×10^6 /construct and 3×10^6 /construct, 1×10^6 /construct under BMP9 stimulation at an MOI of 2.3 was adequate to promote efficacious new bone formation.

Histologically, H&E staining analysis revealed that the DBM constructs injected with BMP9-stimulated PDLSCs formed evident trabecular bone in all groups, while the significant augmentation of newly formed bone correlated with the increased MOIs of BMP9, and the 1×10^6 cells/construct under BMP9 stimulation at an MOI of 2.3 were adequate to form new bone tissue, nearly filling the whole defect area of DBM constructs (Fig. 7A). Masson trichrome staining analysis further confirmed that the DBM constructs injected with 1×10^6 PDLSCs under BMP9 stimulation at an MOI of 2.3 could form apparently mature and well-mineralized bony masses (Fig. 7B). The immunohistochemical staining assays revealed the expression of osteogenic marker osteocalcin (OCN), which was also in consistent with the results (Additional file 1: Fig. S5A, B). Moreover, the presence of newly formed blood vessels was further verified, as the expression of CD31 and α -SMA was detected in the regenerative tissues by immunohistochemical staining (Fig. 8A, B). Similar to the H&E staining and Masson trichrome staining analyses, the enhanced positive staining of CD31 and α -SMA correlated with the increased BMP9 MOIs, consistent with the fact that BMP9 has both osteogenic and angiogenic activities [46]. In addition, compared to cell doses at 2×10^6 /construct and 3×10^6 /construct, 1×10^6 /construct was adequate to promote efficacious new blood vessel formation. These results demonstrated that an optimal dose of PDLSCs under a specific extent of BMP9 stimulation was efficacious for both new bone and new blood vessel formation in DBM constructs.

Discussion

In the present study, we prepared the DBM from porcine lumbar vertebrae bone and fabricated it into a cylinder-shaped construct to be the modified ectopic system, as well as the ectopic intrabony defect repair model. Then, we explored the suitable stem cell sources among three types of hDMSCs and optimized the combination of PDLSCs and BMP9 for efficacious osteogenic regeneration based on this ectopic intrabony defect model. We found that BMP9-stimulated PDLSCs yielded the most robust new bone formation among the three types of hDMSCs, and an optimal dose of PDLSCs under a specific extent of BMP9 stimulation was adequate to promote efficacious new bone and new blood vessel formation in DBM constructs.

Traditionally, bone healing has been studied based on the construction of orthotopic bone defects [47], while the construction of orthotopic bone defects is indeed laborious and costly if not possible. Compared to the common orthotopic locations at the calvarium, radius and the femur, the bone defect at maxillofacial sites could be more difficult and required more elaborate surgical procedures. Thus, inspired from the orthotopic maxillofacial intrabony defects, mimicking these orthotopic intrabony defects into a simple and effective model to evaluate various candidates for bone regeneration should be meaningful, which could also reduce the number of animals used and improve welfare standards in the future studies. Besides, the ectopic system is widely used for the evaluation of new bone formation in tissue engineering therapies as an alternative, which is easily handled with the price of lacking a bony environment [10]. To solve these conflicts, we modified the ectopic system with the use of DBM to develop a container-like construct, which could be an ectopic intrabony defect model and enable us to easily inject the repair materials into the construct. As a commonly used material, DBM has been previously investigated to supply a microenvironment of bone tissue containing collagen (mainly type I), ECM proteins and growth factors, including bone morphogenetic proteins (BMPs) and vascular endothelial growth factor (VEGF) [12]. In addition, DBM-based materials have been demonstrated to be chemotactic for stem/progenitor cells and

(See figure on next page.)

Fig. 5 BMP9-stimulated PDLSCs exhibited the most potent osteogenic activity in DBM constructs. Eight weeks after the cell suspension injection, the animals were killed. Both the newly formed masses and DBM constructs were retrieved, fixed in formalin, and subjected to μ CT imaging. **A** Schematic representation of the procedure for extracting new bone from the whole construct. **B** 3D reconstruction was performed for all scanned samples. Representative 3D μ CT images of the new bone tissues that had separated from whole constructs (2×10^6 cells-BMP9 1.4/DBM construct). **C** Representative density distribution images of the new bone separated from whole constructs. **D** and **E** The average new bone volume fraction (BV/TV) and radiographic density (in Hounsfield units (HU)) were analyzed using Mimics Research 19.0 software. All values are the means \pm SDs; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$






Fig. 5 (See legend on previous page.)

are supposed to be beneficial to endogenous stem cell recruitment, similar to the in vivo bone defect environment [48, 49]. Thus, DBM can provide an inductive bony environment for new bone and new vasculum regeneration [50]. Our micro-CT images showed the formation of a large amount of new bone in the DBM construct containing PBS without cells. This result confirmed the osteoconduction and osteoinduction of our designed DBM construct. Moreover, to recapitulate the traditional ectopic osteogenesis procedure, we subcutaneously implanted plain DBM constructs (without cells) into athymic nude mice in advance and then injected the cell suspension into the central area of the construct 7 days later. In this way, we facilitated the generation of vascularized tissue utilizing the in vivo environment as a bioreactor to enable the internal environment of the DBM constructs to mimic the orthotopic systems [51–53].

Several species and sources have been used to prepare DBM, including bovine femurs, bovine tibiae, goat articular cartilage and human epiphyseal bone [54, 55]. In this article, we further optimized DBM constructs prepared from porcine L4–L5 vertebrae, which have been demonstrated to be the most similar to that of humans and feel the same as living people [56]. The part of cancellous bone in porcine lumbar vertebrae was selected; in that cancellous bone is reported to be the position at which 80% of bone remodeling processes occur [57]. The cancellous part of the porcine lumbar vertebrae was confirmed to possess a uniformly trabecular bone structure under micro-CT analysis, which allowed the DBM to construct optimal properties of naturally open and interconnected porous structures to promote bone and vessel formation.

The key points in the development of novel tissue engineering therapy are to determine the suitable sources and doses of seed cells needed [58]. For the regeneration of maxillofacial bone defect, PDLSCs, DPSCs and SCAPs could be perfectly efficient candidates and are popularly studied hDMSCs that possess various differential abilities [59–63]. All three hDMSCs have been analyzed for osteogenic differentiation. Our qPCR results revealed that these three hDMSCs could all response to the BMP9-mediated osteogenic signaling. However, the comparison of the osteogenic activity among them was doubtful in the reported literature.

Hu L et al. found that DPSCs, PDLSCs and SCAP cell sheets have similar characteristics in vitro, but their osteogenic and angiogenic characteristics are different in vivo [64]. Moreover, other previous studies have revealed that PDLSCs exhibit stronger osteogenic activity than DPSCs in in vitro systems [14]. Similarly, in the present study, the results of BMP9-stimulated PDLSCs yielding the most robust new bone formation among the three hDMSCs in the modified ectopic system should be reasonable.

Another highlight of this study is that the DBM constructs can also be used as repeatable and controlled intrabony defects to screen for appropriate doses of seed cells under specific extents of biofactor stimulation. We demonstrated that PDLSCs with different doses of cell numbers varying from 1×10^6 /construct to 3×10^6 /construct under BMP9 stimulation at an MOI of 2.3 could nearly repair the whole defect area inside the DBM construct and even exceed the height of the construct. In addition, histological staining revealed that these groups could all generate many new blood vessels and bone tissues both inside and outside the construct, which demonstrated the great integrative repair capacity of the regenerative organization to the DBM construct. These results suggested that an optimal number of seed cells under a specific extent of BMP9 stimulation is enough to repair critical-sized bone defects. In MSC therapy, the seed cell sources and sub-optimal doses usually exhibit inconsistent outcomes in distinct clinical trials [65]. Meanwhile, MSC treatment is costly, and the greater the demand for seed cells, the higher the price. Therefore, exploration of the appropriate MSC source and dose under a certain extent of biological factor stimulation for the repair of specific-sized defects is essential in engineering therapy. Collectively, the DBM constructs designed in our study can be used not only as a modified ectopic system but also as a novel ectopic critical-sized intrabony defect to optimize the suitable dose of seed cells, which is enough for the bone healing of specific-sized defects. The size of the DBM constructs can be easily adjusted according to the demand. However, due to the objective of our study, mechanical force, which was significant for bone formation, was left out. Since the DBM constructs contained BMP9-stimulated hPDLSCs exhibited

(See figure on next page.)

Fig. 6 An optimal dose of BMP9-stimulated PDLSCs is adequate for bone formation in DBM constructs. **A** Representative fluorescent signals of PDLSCs with different MOIs of Ad-BMP9. Primary human PDLSCs were infected with Ad-BMP9 for 1 d. **B** The subcutaneously implanted DBM constructs loaded with infected cells were harvested at 8 weeks post injection, and 3D μ CT images of the whole constructs were reconstructed. The yellow part is the construct, while the blue part is the newly formed bony mass. **C** and **D** The average BV/TV and radiographic density (in Hounsfield units (HU)) were analyzed using Mimics Research 19.0 software. **E** Reconstructed 3D μ CT images showing the heights of new bone formation. **F** The heights of new bone were analyzed using Mimics Research 19.0 software. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, # no statistical significance




Fig. 6 (See legend on previous page.)




Fig. 7 Histological analysis of the newly formed tissues with different cell concentrations and distinct BMP9 MOIs. After μ CT imaging was completed, the samples were decalcified and subjected to paraffin-embedded sectioning for histologic evaluation, including **A** H&E staining and **B** Masson staining. The representative images show fields of new tissue formation inside the DBM constructs. TB, trabecular bone; OM, osteoid matrix. Scale bar = 100 μ m




Fig. 8 Immunohistochemical staining of the newly formed tissues with different cell concentrations and distinct BMP9 MOIs. **A** Representative immunohistochemical staining images of CD31 and **B** α-SMA. The newly formed blood vessels are indicated with arrows. Scale bar = 50 μm

robust osteogenic activity, we will try to develop them for orthotopic maxillofacial defects repair in the next phase of our investigation. In addition, popular and effective strategies, such as the use of electrospinning [12] and hydrogels, can also be utilized to further modify DBM constructs in future research.

Conclusions

In summary, the present study successfully fabricated a cylinder-shaped DBM construct from porcine lumbar vertebrae to modify the ectopic system and mimic the orthotopic maxillofacial intrabony defect. The use of constructs in optimizing the combination of suitable hDMSCs and BMP9 for intrabony defect repair revealed that BMP9-stimulated PDLSCs exhibited the most effective bone regeneration among the three hDMSCs, while an optimal dose of PDLSCs under a specific extent of BMP9 stimulation was adequate for new bone formation, excellent osseointegration and vascularization in DBM constructs. Therefore, using the modified ectopic system to further explore the optimized combination of suitable seed cells and biological factors for bone defect repair could provide significant new insights to develop efficacious bone tissue engineering therapies.

Abbreviations

DBM: Decellularized bone matrix; hDMSCs: Human dental mesenchymal stem cells; DPSCs: Dental pulp stem cells; PDLSCs: Periodontal ligament stem cells; SCAPs: Apical papillary stem cells; BMP9: Bone morphogenetic protein 9; rsDBM: Ring-shaped decellularized and demineralized bone matrix; Ad-BMP9: Adenoviruses expressing BMP9; Ad-GFP: Adenoviruses green fluorescent protein; MOI: Multiplicity of infection; BV/TV: Bone volume fraction; HU: Hounsfield units; H&E: Hematoxylin and eosin; VEGF: Vascular endothelial growth factor; FITC: Fluorescein isothiocyanate; PBS: Phosphate-buffered saline; 2D: Two-dimensional; 3D: Three-dimensional; RT-qPCR: Real-time quantitative polymerase chain reaction; cDNA: Complementary DNA; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; ID1: Inhibitor of differentiation 1; ID2: Inhibitor of differentiation 2; CTGF: Connective tissue growth factor; RUNX2: Runt-related transcription factor 2; OPN: Osteopontin; ALP: Alkaline phosphatase; OSX: Osterix; SPF: Specific pathogen free; OCN: Osteocalcin; DAB: Diaminobenzidine; IOD: Integrated optical density.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13287-022-03221-3>.

Additional file 1. Fig. S1: The effect of BMP9 on the osteogenic differentiation ability of hDMSCs in vitro. (A) BMP9 stimulated the expression of early responsive target genes in hDMSCs. Human DPSCs, SCAPs and PDLSCs were infected with Ad-GFP and Ad-BMP9 for 24h. The expression levels of ID1, ID2 and CTGF in different groups were evaluated by qPCR. (B) BMP9 stimulated the expression of osteogenic genes in hDMSCs. The expression levels of RUNX2, OPN, ALP and OSX in different groups were evaluated by qPCR on days 3 and 7. The assays were carried out in three independent experiments. All data are the means \pm SDs; * P <0.05 and ** P <0.01. **Fig. S2:** Reconstructed 3D micro-CT images showing the heights of new bone formation. Representative images are shown. **Fig. S3:** The heights of new bone were analyzed using Mimics Research 19.0 software. All values are the means \pm SDs; * P < 0.05, ** P < 0.01, *** P < 0.001.

Fig. S4: Reconstructed 3D micro-CT images of the whole constructs. The yellow regions represent the plain DBM constructs, while the blue regions are indicative of newly formed bony masses. Representative images are shown. **Fig. S5:** Immunohistochemical staining of osteogenic marker in newly formed tissues. (A) Representative immunohistochemical staining images of osteocalcin (OCN). Scale bar=50 μ m. (B) The OCN positive cells were quantified by IOD (Integrated Optical Density) with Image-Pro Plus. All values are the means \pm SDs; *** P < 0.001, # no statistical significance. **Table S1:** Primer sequences.

Acknowledgements

Not applicable

Author contributions

YXZ contributed to the study design, data acquisition, analysis and interpretation and drafting of the manuscript; WPL and LWZ contributed to the data acquisition and analysis and critical revision of the manuscript; JH and LN contributed to the data acquisition and analysis and critically revised the manuscript; HZ, XT, YCJ, YML, TYZ, ZHY and TCH contributed to the data acquisition and analysis and drafted the manuscript; and HMZ contributed to the study conception and design and data interpretation, as well as drafted and critically revised the manuscript. All authors read and approved the final manuscript.

Funding

The reported work was supported in part by research grants from the National Natural Science Foundation of China (#81870758 to HZ, #32070539 to WL), Natural Science Foundation of Chongqing (#cstc2021jcyjmsxmX0560 to HZ) and Scientific and Technological Research Program of Chongqing Municipal Education Commission (#KJZD-K201900402 to TZ).

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

The human dental mesenchymal stem cell collections were approved by the Ethics Committee of The Affiliated Hospital of Stomatology, Chongqing Medical University [CQHS-REC-2022 (LSNo.15)]. The animal study protocol was approved by the Ethics Committee of The Affiliated Hospital of Stomatology, Chongqing Medical University [CQHS-REC-2022 (LSNo.15)].

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, The Affiliated Hospital of Stomatology of Chongqing Medical University, 426 Songshibei Road, Chongqing 401147, China. ²Department of Pediatric Dentistry, The Affiliated Hospital of Stomatology, Chongqing Medical University, Chongqing, China. ³Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing, China. ⁴Molecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL 60637, USA.

Received: 20 July 2022 Accepted: 12 December 2022

Published online: 27 December 2022

References

- Zhang M, Lin RC, Wang X, Xue JM, Deng CJ, Feng C, et al. 3D printing of Haversian bone-mimicking scaffolds for multicellular delivery in bone regeneration. *Sci Adv.* 2020;6(12):66.

2. Wang ZF, Weng YM, Lu SJ, Zong CL, Qiu JY, Liu YP, et al. Osteoblastic mesenchymal stem cell sheet combined with Choukroun platelet-rich fibrin induces bone formation at an ectopic site. *J Biomed Mater Res B Appl Biomater*. 2015;103(6):1204–16.
3. Xian H, Luo DQ, Wang L, Cheng WK, Zhai WL, Lian KJ, et al. Platelet-rich plasma-incorporated autologous granular bone grafts improve outcomes of post-traumatic osteonecrosis of the femoral head. *J Arthroplasty*. 2020;35(2):325–30.
4. Salamanna F, Tschon M, Borsari V, Pagani S, Martini L, Fini M. Spinal fusion procedures in the adult and young population: a systematic review on allogenic bone and synthetic grafts when compared to autologous bone. *J Mater Sci Mater Med*. 2020;31(6):66.
5. Tang YW, Lin KC. Management of bone defects due to infected non-union or chronic osteomyelitis with autologous non-vascularized free fibular grafts. *Inj Int J Care Inj*. 2020;51(2):294–300.
6. Abdelmoneim D, Porter GC, Coates DE, Duncan WJ, Waddell JN, Hammer N, et al. The effect of low-processing temperature on the physicochemical and mechanical properties of bovine hydroxyapatite bone substitutes. *Materials*. 2022;15(8):66.
7. Cheng C, Chaaban M, Born G, Martin I, Li Q, Schaefer DJ, et al. Repair of a rat mandibular bone defect by hypertrophic cartilage grafts engineered from human fractionated adipose tissue. *Front Bioeng Biotechnol*. 2022;10:66.
8. Zhang L, Tang J, Sun L, Zheng T, Pu X, Chen Y, et al. Three-dimensional printed tissue engineered bone for canine mandibular defects. *Genes Dis*. 2020;7(1):138–49.
9. Schindeler A, Mills RJ, Bobynd JD, Little DG. Preclinical models for orthopedic research and bone tissue engineering. *J Orthop Res*. 2018;36(3):832–40.
10. Ehnert S, Rinderknecht H, Aspera-Werz RH, Haeussling V, Nussler AK. Use of in vitro bone models to screen for altered bone metabolism, osteopathies, and fracture healing: challenges of complex models. *Arch Toxicol*. 2020;94(12):3937–58.
11. Pakvasa M, Haravu P, Boachie-Mensah M, Jones A, Coalson E, Liao J, et al. Notch signaling: Its essential roles in bone and craniofacial development. *Genes Dis*. 2021;8(1):8–24.
12. Dong CJ, Qiao FY, Chen GB, Lv YG. Demineralized and decellularized bone extracellular matrix-incorporated electrospun nanofibrous scaffold for bone regeneration. *J Mater Chem B*. 2021;9(34):6881–94.
13. Zhang HM, Wang JH, Deng F, Huang EY, Yan ZJ, Wang ZL, et al. Canonical Wnt signaling acts synergistically on BMP9-induced osteo/odontoblastic differentiation of stem cells of dental apical papilla (SCAPs). *Biomaterials*. 2015;39:145–54.
14. Chen QY, Lin JH, Chen QM, Zheng LW, Tang YY, Wang FL, et al. Role of special AT-Rich sequence-binding protein 2 in the osteogenesis of dental mesenchymal stem cells. *Stem Cells Dev*. 2020;29(16):1059–72.
15. Wang L-H, Gao S-Z, Bai X-L, Chen Z-L, Yang F. An up-to-date overview of dental tissue regeneration using dental origin mesenchymal stem cells: challenges and road ahead. *Front Bioeng Biotechnol*. 2022;10:85–5396.
16. Lee H-N, Liang C, Liao L, Tian W-D. Advances in research on stem cell-based pulp regeneration. *Tissue Eng Regen Med*. 2021;18(6):931–40.
17. Chen F-M, Gao L-N, Tian B-M, Zhang X-Y, Zhang Y-J, Dong G-Y, et al. Treatment of periodontal intrabony defects using autologous periodontal ligament stem cells: a randomized clinical trial. *Stem Cell Res Ther*. 2018;7:33.
18. Ramamoorthi M, Bakkar M, Jordan J, Tran SD. Osteogenic potential of dental mesenchymal stem cells in preclinical studies: a systematic review using modified ARRIVE and CONSORT guidelines. *Stem Cells Int*. 2015;6:66.
19. Winning L, Robinson L, Boyd AR, El Karim IA, Lundy FT, Meenan BJ. Osteoblastic differentiation of periodontal ligament stem cells on non-stoichiometric calcium phosphate and titanium surfaces. *J Biomed Mater Res A*. 2017;105(6):1692–702.
20. Li J, Feng J, Liu Y, Thach-Vu H, Grimes W, Hoang Anh H, et al. BMP-SHH signaling network controls epithelial stem cell fate via regulation of its niche in the developing tooth. *Dev Cell*. 2015;33(2):125–35.
21. Huang X, Wang F, Zhao C, Yang S, Cheng Q, Tang Y, et al. Dentinogenesis and tooth-alveolar bone complex defects in BMP9/GDF2 knockout mice. *Stem Cells Dev*. 2019;28(10):683–94.
22. Kang Q, Sun MH, Cheng H, Peng Y, Montag AG, Deyrup AT, et al. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. *Gene Ther*. 2004;11(17):1312–20.
23. Kang Q, Song W-X, Luo Q, Tang N, Luo J, Luo X, et al. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. *Stem Cells Dev*. 2009;18(4):545–U33.
24. Luu HH, Song W-X, Luo X, Manning D, Luo J, Deng Z-L, et al. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. *J Orthop Res*. 2007;25(5):665–77.
25. Cheng HW, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). *J Bone Joint Surg Am Vol*. 2003;85A(8):1544–52.
26. Mostafa S, Pakvasa M, Coalson E, Zhu A, Alverdy A, Castillo H, et al. The wonders of BMP9: from mesenchymal stem cell differentiation, angiogenesis, neurogenesis, tumorigenesis, and metabolism to regenerative medicine. *Genes Dis*. 2019;6(3):201–23.
27. Nie L, Yang X, Duan L, Huang EY, Zhou PF, Luo WP, et al. The healing of alveolar bone defects with novel bio-implants composed of Ad-BMP9-transfected rDFCs and CHA scaffolds. *Sci Rep*. 2017;7:66.
28. Cabral MCT, Costa MA, Fernandes MH. In vitro models of periodontal cells: a comparative study of long-term gingival, periodontal ligament and alveolar bone cell cultures in the presence of beta-glycerophosphate and dexamethasone. *J Mater Sci Mater Med*. 2007;18(6):1079–88.
29. About I, Bottero MJ, de Denato P, Camps J, Franquin JC, Mitsiadis TA. Human dentin production in vitro. *Exp Cell Res*. 2000;258(1):33–41.
30. Koutsoumparis AE, Patsiarika A, Tsingotjidou A, Pappas I, Tsiftoglou AS. Neural differentiation of human dental mesenchymal stem cells induced by ATRA and UDP-4: a comparative study. *Biomolecules*. 2022;12(2):66.
31. Valatkaite E, Bausyte R, Vitkeviciene A, Ramasauskaite D, Navakauskiene R. Decidualization potency and epigenetic changes in human endometrial origin stem cells during propagation. *Front Cell Dev Biol*. 2021;9:66.
32. Khalid S, Ekram S, Salim A, Chaudhry GR, Khan I. Transcription regulators differentiate mesenchymal stem cells into chondroprogenitors, and their in vivo implantation regenerated the intervertebral disc degeneration. *World J Stem Cells*. 2022;14(2):163–82.
33. Zhang J, Zhang S, Yang Y, Liu L. Transplantation of umbilical cord blood-derived mesenchymal stem cells as therapy for adriamycin induced-cardiomyopathy. *Bioengineered*. 2022;13(4):9564–74.
34. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. *Nat Protoc*. 2007;2(5):1236–47.
35. Zhao C, Wu NN, Deng F, Zhang HM, Wang N, Zhang WW, et al. Adenovirus-mediated gene transfer in mesenchymal stem cells can be significantly enhanced by the cationic polymer polybrene. *PLoS ONE*. 2014;9(3):66.
36. Yu T, Gao H, Liu T, Huang YD, Wang C. Effects of immediately static loading on osteointegration and osteogenesis around 3D-printed porous implant: a histological and biomechanical study. *Mater Sci Eng C Mater Biol Appl*. 2020;108:66.
37. Giambini H, Dragomir-Daescu D, Huddleston PM, Camp JJ, An KN, Nassr A. The effect of quantitative computed tomography acquisition protocols on bone mineral density estimation. *J Biomech Eng Trans ASME*. 2015;137(11):66.
38. Morgan EF, Bayraktar HH, Keaveny TM. Trabecular bone modulus-density relationships depend on anatomic site. *J Biomech*. 2003;36(7):897–904.
39. Peng Y, Kang Q, Cheng HW, Li XM, Sun MH, Jiang W, et al. Transcriptional characterization of bone morphogenetic proteins (BMPs)-mediated osteogenic signaling. *J Cell Biochem*. 2003;90(6):1149–65.
40. Peng Y, Kang Q, Luo Q, Jiang W, Si WK, Liu BA, et al. Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. *J Biol Chem*. 2004;279(31):32941–9.
41. Luo Q, Kang Q, Si WK, Jiang W, Park JK, Peng Y, et al. Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. *J Biol Chem*. 2004;279(53):55958–68.
42. Sharff KA, Song W-X, Luo X, Tang N, Luo J, Chen J, et al. Hey1 basic helix-loop-helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. *J Biol Chem*. 2009;284(1):649–59.

43. Huang E, Zhu G, Jiang W, Yang K, Gao Y, Luo Q, et al. Growth hormone synergizes with BMP9 in osteogenic differentiation by activating the JAK/STAT/IGF1 pathway in murine multilineage cells. *J Bone Miner Res.* 2012;27(7):1566–75.
44. Hu N, Jiang D, Huang E, Liu X, Li R, Liang X, et al. BMP9-regulated angiogenic signaling plays an important role in the osteogenic differentiation of mesenchymal progenitor cells. *J Cell Sci.* 2013;126(2):532–41.
45. Zhang L, Luo Q, Shu Y, Zeng Z, Huang B, Feng Y, et al. Transcriptomic landscape regulated by the 14 types of bone morphogenetic proteins (BMPs) in lineage commitment and differentiation of mesenchymal stem cells (MSCs). *Genes Dis.* 2019;6(3):258–75.
46. Xiao H, Wang X, Wang C, Dai G, Zhu Z, Gao S, et al. BMP9 exhibits dual and coupled roles in inducing osteogenic and angiogenic differentiation of mesenchymal stem cells. *Biosci Rep.* 2020;40:66.
47. Moreno-Jimenez I, Hulsart-Billstrom G, Lanham SA, Janeczek AA, Kontouli N, Kanczler JM, et al. The chorioallantoic membrane (CAM) assay for the study of human bone regeneration: a refinement animal model for tissue engineering. *Sci Rep.* 2016;6:66.
48. Pacelli S, Basu S, Whitlow J, Chakravarti A, Acosta F, Varshney A, et al. Strategies to develop endogenous stem cell-recruiting bioactive materials for tissue repair and regeneration. *Adv Drug Deliv Rev.* 2017;120:50–70.
49. Cramer MC, Badylak SF. Extracellular matrix-based biomaterials and their influence upon cell behavior. *Ann Biomed Eng.* 2020;48(7):2132–53.
50. Kuang Z, Dai G, Wan R, Zhang D, Zhao C, Chen C, et al. Osteogenic and antibacterial dual functions of a novel levofloxacin loaded mesoporous silica microspheres/nano-hydroxyapatite/polyurethane composite scaffold. *Genes Dis.* 2021;8(2):193–202.
51. Reichenberger MA, Harenberg PS, Pelzer M, Gazyakan E, Ryssel H, Germann G, et al. Arteriovenous loops in microsurgical free tissue transfer in reconstruction of central sternal defects. *J Thorac Cardiovasc Surg.* 2010;140(6):1283–7.
52. Laschke MW, Menger MD. Prevascularization in tissue engineering: current concepts and future directions. *Biotechnol Adv.* 2016;34(2):112–21.
53. Weigand A, Horch RE, Boos AM, Beier JP, Arkudas A. The arteriovenous loop: engineering of axially vascularized tissue. *Eur Surg Res.* 2018;59(3–4):286–99.
54. Abedin E, Lari R, Shahri NM, Fereidoni M. Development of a demineralized and decellularized human epiphyseal bone scaffold for tissue engineering: a histological study. *Tissue Cell.* 2018;55:46–52.
55. Freeman FE, Browe DC, Diaz-Payno PJ, Nulty J, Von Euw S, Grayson WL, et al. Biofabrication of multiscale bone extracellular matrix scaffolds for bone tissue engineering. *Eur Cell Mater.* 2019;38:168–87.
56. Sateri T, Nurro J, Hatinen OP, Hakulinen M, Leinonen V, Elomaa AP. Ex vivo porcine models are valid for testing and training microsurgical lumbar decompression techniques. *World Neurosurg.* 2021;155:E64–74.
57. Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. *Therap Adv Musculoskelet Dis.* 2016;8(6):225–35.
58. Markides H, Foster NC, McLaren JS, Hopkins T, Black C, Oreffo ROC, et al. Short-term evaluation of cellular fate in an ovine bone formation model. *Cells.* 2021;10(7):66.
59. Zhou Y, Huttmacher DW, Sae-Lim V, Zhou Z, Woodruff M, Lim TM. Osteogenic and adipogenic induction potential of human periodontal cells. *J Periodontol.* 2008;79(3):525–34.
60. Irfan M, Kim J-H, Marzban H, Reed DA, George A, Cooper LF, et al. The role of complement C5a receptor in DPSC odontoblastic differentiation and in vivo reparative dentin formation. *Int J Oral Sci.* 2022;14(1):66.
61. Ahmadi F, Salmasi Z, Mojarad M, Eslahi A, Tayarani-Najaran Z. G-CSF augments the neuroprotective effect of conditioned medium of dental pulp stem cells against hypoxic neural injury in SH-SY5Y cells. *Iran J Basic Med Sci.* 2021;24(12):1743–52.
62. Yong Z, Kuang G, Fengying S, Shoumei X, Duohong Z, Jiakai H, et al. Comparison of the angiogenic ability between SHED and DPSC in a mice model with critical limb ischemic. *Tissue Eng Regen Med.* 2022;6:66.
63. Smeda M, Galler KM, Woelflick M, Rosendahl A, Moehle C, Lenhardt B, et al. Molecular biological comparison of dental pulp- and apical papilla-derived stem cells. *Int J Mol Sci.* 2022;23(5):66.
64. Hu L, Zhao B, Gao Z, Xu J, Fan Z, Zhang C, et al. Regeneration characteristics of different dental derived stem cell sheets. *J Oral Rehabil.* 2020;47:66–72.
65. Yuan M, Hu X, Yao L, Jiang Y, Li L. Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease. *Stem Cell Res Ther.* 2022;13(1):179.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

